|
On the Record "This most recent activity only increases the amount of
attention drug pricing is likely to get on the campaign trail. The president
is likely to focus on the EO and future rulemaking in the political context,
despite the fact that policy change has yet to be made." — Elizabeth Carpenter, head of advisory services at Avalere,
spoke with AIS's RADAR on
Drug Benefits about why the president's 'most favored nation'
drug pricing order won't have much of an actual impact on the industry. Subscribers may read the RADAR on Drug Benefits article in which this quote appeared online. Learn more about subscribing to AIS Health's
publications. |
No comments:
Post a Comment